AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) investors are quaking today in the upshot of earnings not so far off the mark from second quarter expectations. …
Cempra Inc (NASDAQ:CEMP) shares are rising close to 6% today on back of the biotech firm’s reveal that Phase 3 data read-outs in …
Roth Capital analyst Michael Higgins was out pounding the table on shares of Palatin Technologies, Inc. (NYSEMKT:PTN) Tuesday, resuming coverage with a Buy rating and a …
Late last week, Synergy Pharmaceuticals Inc (NASDAQ:SGYP) announced the FDA approval of its lead drug Trulance (plecanatide) for the treatment of adults with …
After Synergy Pharmaceuticals Inc (NASDAQ:SGYP) yielded positive Phase 3 top-line data in the first of two pivotal Phase 3 trials in adults with …
Cempra Inc (NASDAQ:CEMP) shares went on a roller-coaster ride today after the FDA’s Antimicrobial Drugs Advisory Committee voted 7-6 that solithromycin’s efficacy outweighs its risks …
In a research report released today, Roth Capital analyst Michael Higgins resumed coverage on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with a Neutral rating on …
Mast Therapeutics Inc (NYSEMKT:MSTX) is in a strong position on the back of two successful Phase II studies for its pipeline drug AIR001, …
Mast Therapeutics Inc (NYSEMKT:MSTX) just announced to frustrated investors that EPIC results for its Sickle Cell pipeline drug vepoloxamer are pushed back now …
What does the future hold for Mast Therapeutics Inc (NYSEMKT:MSTX)? Roth Capital analyst Michael Higgins weighs in on the biotech company, providing investors a summary …
